Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

Key Points

• The aim is to evaluate the efficacy of sacituzumab govitecan combined with pembrolizumab compared to standard chemotherapy.
• Conducted a clinical trial with untreated patients having PD-L1-positive advanced triple-negative breast cancer.
• Compared treatment outcomes between sacituzumab govitecan plus pembrolizumab and chemotherapy plus pembrolizumab.
• Measured progression-free survival as the primary outcome.
• Sacituzumab govitecan plus pembrolizumab showed significantly longer progression-free survival than chemotherapy plus pembrolizumab.
• Treatment was specifically effective among PD-L1-positive patients.

Abstract